Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenowayXPAR:ALGEN +0.40%70 EV-to-EBIT is 23.98 as of Sep. 01, 2026, which is 95% above its 10-year median of 12.31. GuruFocus rates XPAR:ALGEN with a GF Score™ of 70/100 and a GF Value™ of €2.98 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 366 Biotechnology companies, Genoway ranks worse than 63.39% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genoway's Enterprise Value is €37.32 Mil.
Genoway's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €1.56 Mil. Therefore, Genoway's EV-to-EBIT for today is 23.98.
The historical rank and industry rank for Genoway's EV-to-EBIT or its related term are showing as below:
XPAR:ALGEN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -146.49 Med: 12.31 Max: 55.52
Current: 23.98
During the past 13 years, the highest EV-to-EBIT of Genoway was 55.52. The lowest was -146.49. And the median was 12.31.
XPAR:ALGEN's EV-to-EBIT is ranked worse than 63.39% of 366
companies
in the Biotechnology industry
Industry Median: 15.55
vs XPAR:ALGEN: 23.98
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Genoway's Enterprise Value for the quarter that ended in Dec. 2025 was €39.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genoway's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €1.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genoway EV-to-EBIT Related Terms
Genoway EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Genoway's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALGEN vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Genoway's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genoway EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genoway's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genoway's EV-to-EBIT falls into.
Genoway's current Enterprise Value is €37.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genoway's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €1.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genoway (XPAR:ALGEN) has a EV-to-EBIT of 23.98 as of Sep. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genoway and its competitors. This is 95% above median its historical median of 12.31. According to the industry distribution chart, Genoway ranks #232 out of 366 companies in the Biotechnology industry, placing it in the top 63.4%.
Is Genoway's EV-to-EBIT too high?
Genoway's current EV-to-EBIT of 23.98 is 95% above median its 10-year median of 12.31. The Biotechnology industry median EV-to-EBIT is 15.55. Genoway's value of 23.98 is 54.2% above this industry median. Based on the distribution chart, Genoway ranks #232 out of 366 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genoway has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genoway's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genoway ranks #232 out of 366 companies for EV-to-EBIT. This places Genoway in the lower half of its industry. The industry median EV-to-EBIT is 15.55. Genoway's value of 23.98 is 54.2% above this benchmark. While the company's 10-year median is 12.31 vs. the industry median of 15.55, Genoway has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genoway's current EV-to-EBIT of 23.98 is 54.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genoway and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genoway's current EV-to-EBIT is 23.98, which is 95% above median its own 10-year median of 12.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genoway stock overvalued right now?
Based on GuruFocus' analysis, Genoway (XPAR:ALGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.98, compared to a current price of €2.48 — trading 16.8% below its estimated fair value. The current EV-to-EBIT is 23.98, which is 95% above median its 10-year median of 12.31 and 54.2% above the Biotechnology industry median of 15.55. Genoway's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Genoway (XPAR:ALGEN), the current EV-to-EBIT is 23.98 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genoway (XPAR:ALGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Genoway stock appears to be undervalued.
The current stock price of €2.48 is trading 16.8% below its estimated GF Value™ of €2.98.
GuruFocus considers Genoway to be Modestly Undervalued.
Key valuation signals for XPAR:ALGEN:
EV-to-EBIT: 23.98 (95% above median its 10-year median of 12.31)
GF Value™: €2.98 vs. price of €2.48 (16.8% below fair value)
Industry Position: 54.2% above the Biotechnology median (#232 of 366)
No single metric tells the full story. See the XPAR:ALGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries.
70GF Score
Get the complete analysis for XPAR:ALGEN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALGEN has been successfully added to your 
